Review Series


Jump To:


The Blood Review Series are collections of articles that highlight topics of significant interest in the field of hematology. Each series provides concise, critical, and insightful overviews of emerging advances in areas of basic or clinical research.

Single-Cell Technology Meets Hematology

Drs. Margaret A. Goodell and David M. Bodine introduce this review series on Single-Cell Technology Meets Hematology covers the revolutionary impact of single-cell technologies on our understanding of normal and disrupted hematopoiesis. The authors discuss emerging views about hematopoiesis at the single-cell level and compare these observations with the classic hierarchical model under conditions of normal and abnormal hematopoiesis.

Published March 28, 2019 - Blood 133:13


Myelodysplastic Syndromes

Introduced by Bob Löwenberg, this review series on Myelodysplastic Syndromes presents the range of new insights into the genetics, pathogenesis, and treatment of this heterogeneous and challenging disease.

Published March 7, 2019 - Blood 133:10


Advances in Multiple Myeloma

Hervé Avet-Loiseau introduces this series on advances in multiple myeloma. Written by experts in the field, this review series deals with clinically timely questions. What is the optimal imaging approach at diagnosis and follow-up? Is frontline high-dose melphalan with stem cell support still the standard of care? With so many novel drugs, are we ready for patient-adjusted treatment?

Published February 14, 2019 - Blood 133:7


New Therapeutics for Inherited and Acquired Bleeding Conditions

Introduced by Thomas L. Ortel, this review series on new therapeutics for inherited and acquired bleeding conditions highlights the increasing number of options available to treat patients with inherited as well as acquired bleeding disorders.

Published January 31, 2019 - Blood 133:5


Iron Metabolism and Its Disorders

The five articles in this review series offer comprehensive insights into the landscape of emerging research in iron metabolism and the clinical management of patients with iron disorders.

Published January 3, 2019 - Blood 133:1


How I Treat Series on Sickle Cell Disease and Thalassemia

Survival of patients with sickle cell disease and thalassemia has significantly improved, putting patients at risk for new disease-related complications when they grow older. We present a series of How I Treat articles that highlight the unique diagnostic and therapeutic issues associated with patients with hemoglobinopathies who survive into adulthood.

Published October 26, 2018 - Blood 132:17


Adolescent and Young Adult Malignant Hematology

Treating hematologic malignancies in adolescent and young adults (AYA) has unique biologic, therapeutic, and social challenges. Introduced with an editorial by Blood Associate Editor Jorge Cortes, this review series focuses on these unique features in discussing the approach to the AYA population in treating leukemias and lymphomas, with a final review focused on the general psychosocial challenges of this population.

Published July 26, 2018 - Blood 132:4


Nontraditional Roles for the Hemostatic System in the Vessel Wall

Introduced with an editorial by Blood Associate Editor José A. López, this review series explores the growing understanding of the diverse roles of the hemostatic system outside the realm of clotting and bleeding. The reviews explore the important roles of coagulation proteins and platelets in hematopoietic stem cell development, vessel wall formation, vascular endothelial function, and neuroprotection.

Published July 12, 2018 - Blood 132:2


Emerging Immunotherapies for Hematologic Diseases

Edited with an introduction by Blood Associate Editor Catherine M. Bollard, and Blood authors Sophie Paczesny and Steven Z. Pavletic, we present a review series on emerging immunotherapies for hematologic disease, discussing chimeric antigen receptor T cells and their toxicities, vaccine therapies, and cellular therapies for graft-versus-host disease.

Published June 14, 2018 - Blood 131:24


Biological Insights into Lymphoid Tumors

Introduced with an editorial by Blood Associate Editor Freda K. Stevenson, this series of four reviews on biologic insights into lymphoid tumors highlights recent insights into a range of lymphoid tumors in an era of explosively increasing knowledge of genetics, epigenetics, and tumor-environment interactions and clinical testing of precision drug targeting.

Published May 24, 2018 - Blood 131:21


Update on Hodgkin Lymphoma

Introduced with an editorial by Blood Associate Editor Laurie H. Sehn, the articles in this series of reviews on Hodgkin lymphoma explore advances in biological insights that have led to the identification of novel targets for drug development and enabled more accurate prognostication. They also examine optimization of various therapeutic strategies for early-stage, advanced-stage, and relapsed disease.

Published April 15, 2018 - Blood 131:15


Strategies to Improve GVL Effects

Introduced with an editorial by Blood Associate Editor Robert Zeiser, this review series explores exciting new developments in treatments to enhance graft-versus-leukemia (GVL) effects in hematopoietic cell transplantation, including cellular therapies, antibody-based treatments, and drug-based approaches using tyrosine kinase inhibitors and checkpoint blockade.

Published March 8, 2018 - Blood 131:10


Hematologic Disease at Older Age

Introduced by Dr. Bob Löwenberg, the Series of Reviews published in this issue of Blood is written by leaders in the field and highlights common biologic and clinical concepts related to hematologic disease associated with aging.

Published February 1, 2018 - Blood 131:5


Therapeutic Antibodies

Introduced by Drs. Freda K. Stevenson and Catherine M. Bollard, this series of 6 reviews written by leaders in the field describe the emerging mechanistic insights and therapeutic value of different classes of antibody therapy, including direct antibodies; “accelerator” antibodies against coreceptors; and antibodies reversing regulatory T-cell activity, for a variety of hematological malignancies.

Published January 4, 2018 - Blood 131:1


Precision Hematology

Edited with an introduction by Dr Benjamin L. Ebert, we present a series of reviews focused on precision hematology. This series presents the state of the art usage of genomic techniques for the identification of inherited and acquired mutations guiding the diagnosis and treatment of hematologic disorders, the methods for gathering and storing genomic data, and the ethical considerations in such genomic testing.

Published July 27, 2017 - Blood 130:4


Clinical Platelet Disorders

Introduced by José López and Nancy Berliner, this series of review articles provides an up-to-date examination of several clinical platelet disorders that often perplex clinicians because of their difficulty in diagnosis or complexity in therapy.

Published May 25, 2017 - Blood 129:21


Transcription Factors in Hematopoiesis and Hematologic Disease

Introduced by David Bodine, this set of 6 review articles focuses on 4 hematopoietic transcription factors with critical roles in normal and malignant hematopoiesis. The reviews highlight the fast-moving field of transcription factor biology that is reshaping our understanding of normal and malignant hematology.

Published April 13, 2017 - Blood 129:15


Leukemic Stem Cells

Introduced by Bob Löwenberg, this review series on leukemic stem cells, is a collection of definitive reviews on the biology of stem cells in acute myeloid leukemia, myelodysplasia, and myeloproliferative neoplasms, including their relationship to the marrow microenvironment and their significance for effective leukemia treatment.

Published March 23, 2017 - Blood 129:12


T-Cell Malignancies

This series of comprehensive reviews discusses the molecular pathobiology and molecular genetics of the highly diverse T-cell malignancies, outlines their diagnostic implications, and highlights novel therapeutic strategies.

Published March 2, 2017 - Blood 129:9


Myeloproliferative Neoplasms

Introduced by Dr. Mario Cazzola this comprehensive review series on myeloproliferative neoplasms provides an update on the rapidly evolving understanding of the genetic underpinnings of these diseases and its impact on improving therapy.

Published February 9, 2017 - Blood 129:6


Chronic GVHD: From Pathogenic B-cell Receptor to Novel Therapeutic Targets

New directions of research discussed in this series of reviews aim at targeting B-cell signaling pathways that are operational in chronic graft-versus-host disease (cGVHD).

Published January 5, 2017 - Blood 129:1


Advances in Cell-Based Immune Therapeutics in Hematology

This six-part series, written by leading experts in the field of cell-based immunotherapy, presents three articles discussing the state of the art of chimeric antigen receptor T-cell therapies and their toxicities and three additional articles that highlight other new immunotherapeutic approaches, including cellular therapies to treat post–hematopoietic stem cell transplantation viral infections, natural killer cell therapies for acute leukemia, and the use of gene-modified T cells to block immune evasion in hematologic malignancies.

Published June 30, 2016 - Blood 127:26


Genome Editing in Hematology

The exciting new field of genome editing represents a quantum leap for biology and medicine. A series of four reviews written by experts in the field summarize conceptual, clinical, and ethical aspects of genome editing with a focus on its potential for treating hematologic diseases.

Published May 26, 2016 - Blood 127:21


Updated WHO Classification of Hematological Malignancies

Experts in the field summarize the Updated World Health Organization (WHO) Classification of Hematological Malignancies that incorporates new clinical, prognostic, morphologic, immunophenotypic, and genetic data.

Published May 19, 2016 - Blood 127:20


The Paradox of Indolent B-cell Lymphoma

A comprehensive series of 5 reviews, introduced by Dr. Laurie Sehn, explore the unique biology and management aspects for indolent B-cell lymphoma subtypes.

Published April 28, 2016 Blood 127:17


Megakaryocytes to Platelets in Health and Disease

In this review series, introduced by Dr. Leslie Parise, Blood presents a collection of articles focused on megakaryocytes and platelets and their potential development as in vitro resources for transfusion and for drug delivery.

Published March 10, 2016 - Blood 127:10


Sickle Cell Disease: Challenges and Progress

In this review series, introduced by Dr. Leslie Parise and Dr. Nancy Berliner, leading researchers provide five state-of-the-art updates on important biological, clinical, and therapeutic aspects of sickle cell disease.

Published February 18, 2016: Blood 127:7


Advances in Acute Myeloid Leukemia

Introduced by Dr. Bob Löwenberg and Dr. Jacob Rowe, this review series offers comprehensive updates on the latest insights into the pathobiology of the disease as well as the current and emerging directions of treatment.

Published January 7, 2016 - Blood 127:1


Chronic Lymphocytic Leukemia: Taking a Big Leap Forward

Introduced by Dr. John C. Byrd this review series provides a comprehensive update on the newest insights into the biology of chronic lymphocytic leukemia (CLL) and the emerging treatment scenarios in clinical practice.

Published July 23, 2015 - Blood 126:4


Acute Lymphoblastic Leukemia

Introduced by Dr. Jean Soulier and Dr. Jorge Cortes, this review series highlights recent advances in the field of acute lymphoblastic leukemia (ALL) and their impact on developmental therapeutics. They address molecular precision diagnostics, minimal residual disease detection, genetic variation in childhood ALL, and the newest immunotherapeutic approaches.

Published June 25, 2015 - Blood 125:26


Multiple Myeloma: From the Bench to Bedside

In this review series, introduced by Dr. Jesús San Miguel, leaders in the field of multiple myeloma (MM) discuss the fascinating pathogenetic scenarios of disease development, the evolution of monoclonal gammopathy of undetermined significance and smoldering myeloma to MM, the clinical importance and practice of minimal residual disease response assessment, and current first- and second-line therapeutic strategies.

Published May 14, 2015 - Blood 125:20


Hematopoietic Stem Cells

Introduced by Dr. Margaret Goodell, this review series describes the state of our knowledge of the ontogeny and regulation of hematopoietic stem cells (HSCs) and the role of the bone marrow niche in their development. Other articles discuss xenograft models for studying normal and malignant stem cells and the current state of the art of generation of stem cells from somatic and pluripotent stem cell sources.

Published April 23, 2015 - Blood 125:17


Inherited Bleeding Disorders

Edited and introduced with an editorial by Dr. David Lillicrap, this series reviews the state of the art, basic understanding, and clinical management of von Willebrand disease, hemophilia, and other rare bleeding disorders. It includes the latest molecular understanding of the pathogenesis of congenital bleeding diatheses and recommendations for diagnosis and management, including a therapeutic approach to prophylaxis of bleeding and the clinical management of treatment-induced inhibitors.

Published March 26, 2015 - Blood 125:13


Aggressive B-cell Lymphoma

The term 'aggressive B-cell lymphomas' has been applied to highly proliferative lymphomas that evolve clinically over weeks to months, and have been the focus of important advantages in clinical treatment strategies. The series highlights the evolution of our understanding of the biology of these lymphomas such that they are now defined as a heterogeneous group of diseases that requires tailored therapy. The aim of the series is to elucidate how this improved understanding of pathogenesis is leading to more effective treatment strategies and improved survival.

Published January 1, 2015 - Blood 125:1


Bone Marrow Failure

Bone marrow failure syndromes are characterized by deficient regenerative or maturation abilities of stem and progenitor cells, leading to quantitative and qualitative abnormalities in one or more of the hematopoietic lineages, as well as an increased risk of transformation to leukemia. Recent research has greatly enhanced our understanding of these disorders, leading to better therapies and better clinical outcomes. This series presents comprehensive updates regarding the biology as well as the diagnostic and therapeutic advances in these diseases.

Published October 30, 2014 - Blood 124:18


Advances in Hematopoietic Cell Transplantation

This review series provides a perspective on the successes and challenges of Hematopoietic Cell Transplantation. Despite the amazing progress over the last 40 years that has made HCT a “routine” medical procedure, issues surrounding donor choice, conditioning regimens, and management of graft-versus-host disease persist. In this series, experts from around the world provide insights into the current state of the art of HCT and perspectives on future directions.

Published July 17, 2014 - Blood 124:3


Antibody Derivatives as New Therapeutics for Hematologic Malignancies

In this review series a variety of antibody-derived therapeutics that show promise for the treatment of hematologic malignancies are reviewed in depth.

Published April, 2014 Blood - 123:15-17